Plasma Protein Therapies are unique medicinal products. Their biological origin, their complex production process and unusual cost structure make them very different from traditional pharmaceutical products. Ensuring that governments appropriately recognize the unique nature of plasma protein therapies in their reimbursement policies will ensure the availability and choice of these life-saving therapies to the patients. The documents below provide information on reimbursement related issues.

Sources

   Reimbursement developments in the European Union